Renal Cancer Information Center

Renal Cancer News

Afinitor® Effective Against Metastatic Kidney Cancer (05/18/2009)
According to the results of a Phase II clinical trial, roughly 70% of patients with metastatic renal cell (kidney) cancer experienced either a reduction in detectable cancer or stable disease following treatment with Afinitor® (everolimus). These results were published in Cancer.

Afinitor® Approved for Advanced Kidney Cancer (03/31/2009)
The U.S. Food and Drug Administration has approved Afinitor® oral tablets (everolimus) for the treatment of patients with advanced renal cell carcinoma that has progressed after treatment with Sutent® (sunitinib) or Nexavar® (sorafenib).

Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma (03/25/2009)
In patients with untreated renal cell cancer (RCC), Nexavar® (sorafenib) results in a similar progression-free survival (PFS) to interferon, yet patients experience greater rates of tumor shrinkage and report a better quality of life (QOL) with Nexavar than with interferon. The results of this study were published in the Journal of Clinical Oncology.

Meat, Fat, and Protein Consumption Does Not Increase Risk of Renal Cell Cancer (01/14/2009)
Intake of red meat, processed meat, poultry, or seafood is not associated with a risk of renal cell cancer, according to the results of a study published in the Journal of the National Cancer Institute.

Cardiac Toxicity in Patients with Metastatic Renal Cell Carcinoma Receiving Tyrosine Kinase Inhibitors (11/12/2008)
In a recent single-center study, researchers analyzed the cardiac toxicity associated with the tyrosine kinase inhibitors Sutent® (sunitinib) and Nexavar® (sorafenib) in patients with metastatic renal cell carcinoma and concluded that although the incidence of cardiac damage from these agents may be higher than previously thought, it is manageable with careful monitoring and treatment. The results of this study were published in the November 10, 2008 issue of the Journal of Clinical Oncology.